Anzeige
Meldung des Tages: U.S. Forest Service erteilt Genehmigung: New Amalga tritt in die Entwicklungsphase ein

Orexo Aktie News

Aktie
WKN:  A0HG6G ISIN:  SE0000736415 US-Symbol:  ORXOF Branche:  Pharmazeutika Land:  Schweden
3,235 €
-0,035 €
-1,07%
11:20:36 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
40,25%
KGV
-10,08
Index-Zuordnung
-

Orexo News

05.09.25 - PR Newswire
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication PR Newswire
05.09.25 - PR Newswire
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication PR Newswire
24.07.23 - PR Newswire
Orexo's patent win for ZUBSOLV® appealed
Orexo's patent win for ZUBSOLV® appealed PR Newswire
24.07.23 - PR Newswire
Orexo's patent win for ZUBSOLV® appealed
Orexo's patent win for ZUBSOLV® appealed PR Newswire
14.07.22 - PLX
Orexo Q2 EBIT SEK -49.7 Million
(PLX AI) – Orexo Q2 revenue SEK 147.8 million. • Q2 EBITDA SEK -32.5 million • Q2 EPS SEK -1.04
28.04.22 - PLX
Orexo Q1 EBIT SEK -13.2 Million
(PLX AI) – Orexo Q1 revenue SEK 159.4 million. • Q1 EBITDA SEK 2.8 million • Q1 EPS SEK -0.69
27.01.22 - PLX
Orexo Q4 EBIT SEK -64.1 Million vs. Estimate SEK -51 Million
(PLX AI) – Orexo Q4 revenue SEK 144 million vs. estimate SEK 140 million. • Q4 EBITDA SEK -48.5 million vs. estimate SEK -40 million • Q4 EPS SEK -1.92
16.11.21 - PLX
Orexo to File for OX124 FDA Approval; Sees U.S. Launch in H2 2023
(PLX AI) – Orexo pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers. • OX124 showed a significantly ...
03.11.21 - PLX
Orexo Q3 EBIT SEK -59 Million
(PLX AI) – Orexo Q3 revenue SEK 145.9 million. • Q3 EBITDA SEK -47.4 million • Q3 EPS SEK -1.51
15.07.21 - PR Newswire
Orexo Q2 2021 Interim Report
Orexo Q2 2021 Interim Report PR Newswire
15.07.21 - PR Newswire
Orexo Q2 2021 Interim Report
Orexo Q2 2021 Interim Report PR Newswire
15.07.21 - PLX
Orexo Q2 EBIT SEK -54 Million vs. Estimate SEK -45 Million
(PLX AI) – Orexo Q2 revenue SEK 142.8 million vs. estimate SEK 151 million. • Q2 EBITDA SEK -41.1 million vs. estimate SEK -38 million • Q2 EPS SEK -2.15
12.07.21 - PR Newswire
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® With more than ...
01.07.21 - PR Newswire
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
01.07.21 - PR Newswire
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
02.06.21 - PR Newswire
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents PR Newswire
29.04.21 - PR Newswire
Orexo Q1 2021 Interim Report
Orexo Q1 2021 Interim Report Investing in future growth drivers PR Newswire
23.03.21 - PR Newswire
Orexo publishes Annual Report for 2020
Orexo publishes Annual Report for 2020 PR Newswire
10.02.21 - PR Newswire
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management PR Newswire
10.02.21 - PR Newswire
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management - The Covid-19 pandemic has highlighted the urgent need for additional ...

Newssuche

Videos

newspaper
07.01.26 -12,59%
2026 01 07 10 01 Technical Trading Erdgas Zukauf Short
Erdgas Short Typ: Turbo Open End WKN: VJ0Q9C Hebel: 3,20 Laufzeit: OpenEnd Einstieg: Market ... Mehr »